Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
about
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsApproved Antiviral Drugs over the Past 50 YearsFormulation, pharmacokinetics and pharmacodynamics of topical microbicides.Which topical microbicides for blocking HIV-1 transmission will work in the real world?Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicidesIn vitro activities of candidate microbicides against cell-associated HIVThe nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days.Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsReverse transcriptase inhibitors as potential colorectal microbicides.Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.Influence of long-term stability conditions on microbicidal nucleoside prodrug (WHI-07)-loaded gel-microemulsion.RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.Microbicides: stopping HIV at the gate.Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]).Current and future microbicide approaches aimed at preventing HIV infection in women.In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection.MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1.An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.Facile synthesis of the NNRTI microbicide MC-1220 and synthesis of its phosphoramidate prodrugs.Synthesis, crystal structure, anti-HIV, and antiproliferative activity of new oxadiazole and thiazole analogsAdvanced preformulation investigations for the development of a lead intravaginal bioadhesive polymeric device
P2860
Q21090521-CE78A5CC-2DC1-4884-A926-18767E3719E9Q27755387-B98E20BA-8C34-427A-B08B-E51033CF08B2Q30412592-A53AB257-AB00-4216-B540-EB934A347889Q33253661-B821E3EA-2DB2-4A42-A109-B8FBDFCB26C4Q33598736-4521E477-2AAC-449A-99D3-4AD6407C8161Q33821090-BD474462-3AA4-448E-B539-F253A204F9CFQ33895810-A3548C93-32B8-41A4-99AF-9A9EF8A28B3CQ34737547-DDB3525E-087C-4083-AA5D-FF1DAB3C79FBQ35155093-8BED85B9-191F-45E0-9662-52D104E8680BQ35364134-49D4D814-6ED3-45AE-8E5C-6E899B572954Q35689194-F76649E3-F699-4563-9E1C-DDC7845F4F4FQ36359133-2DE12D29-5C67-48AD-AE57-049AB8B90272Q36482710-249D69F6-6A9F-4780-AC3C-C2F43E12B50FQ36632128-4216927D-3800-4595-B137-2B687725A646Q36744775-BD71E026-D1BF-438E-AFA5-A6470E71F99DQ36749580-049C61BA-3EDA-429D-AF28-4AD2F4C49E3EQ37190754-D3D7D8BB-ED98-4F50-81E9-74D9C6E451DEQ37280337-2F67A227-9707-4D40-919D-24C86843EB2BQ37360804-00650CFD-9B18-4C38-8268-1F0D90392F85Q37428359-45E07FCC-8F13-4D70-AE5A-D5F4911E8F88Q37447338-8B6DACA3-29BA-45A2-9CE6-13B3ED0AB4C3Q37707803-C60BEF1C-1D69-4B74-9030-469C16B9994FQ37980177-4983D169-1720-4FC4-8E4E-88F671E91566Q37984498-C87337E8-D06F-46EE-9909-ABB2EEB78D4CQ39518073-054101DB-8216-47A2-8BEC-4F636D621386Q40081674-C9C50C08-D5F7-4FA2-8D11-6D54B81B48DBQ40165275-35AFBE75-5077-4A94-A919-46F1AF24F1D7Q41040182-5D16C4AE-B342-4462-91A6-6BB82FCB8BF7Q41095817-C9F7E309-F43F-4689-9F6D-A8DD585024D6Q57269151-606A604F-F572-4633-A920-9D84EBC8DDC4Q57382770-5B75C556-23B7-4770-B33B-F734E21F84D2
P2860
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@ast
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@en
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@nl
type
label
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@ast
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@en
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@nl
prefLabel
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@ast
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@en
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@nl
P356
P1476
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
@en
P2093
Osmond J D'Cruz
P304
P356
10.1093/JAC/DKI464
P407
P577
2006-01-23T00:00:00Z